enzalutamiderelugolixUniversity of Oklahoma Health Sciences Centerhigh-risk locally advanced prostate cancerhigh-risk, locally advanced prostate cancerhigh-risk prostate cancerdefinitive local therapy
…therapy), and 18 months of adjuvant therapy with relugolix plus enzalutamide. Primary outcomes include pathologic CR rate and minimal residu…